Atara Biotherapeutics (ATRA) Non-Current Assets (2013 - 2026)

Atara Biotherapeutics (ATRA) has reported Non-Current Assets for 14 consecutive years, with $7.5 million the latest figure, recorded in Q2 2026.

• For the quarter ending Q2 2026, Non-Current Assets fell 38.22% year-over-year to $7.5 million; the trailing twelve-month figure through Jun 2026 stood at $35.1 million (down 75.31% YoY), and the FY2025 full-year result was $8.0 million, down 81.85% from the prior year.
• Non-Current Assets eased to $7.5 million in Q2 2026 per ATRA's latest filing, from $7.8 million in the prior quarter.
• Across five years, Non-Current Assets topped out at $89.1 million in Q2 2022 and bottomed at $7.5 million in Q2 2026.
• Historically, Non-Current Assets has averaged $50.8 million across 5 years, with a median of $56.9 million in 2024.
• The sharpest annual moves came in 2022 and 2025: Non-Current Assets surged 38.27% in 2022, then plunged 81.85% in 2025.
• Over 5 years, Non-Current Assets stood at $81.3 million in 2022, then retreated by 21.77% to $63.6 million in 2023, then sank by 30.54% to $44.2 million in 2024, then slumped by 81.85% to $8.0 million in 2025, then slipped by 6.59% to $7.5 million in 2026.
• According to Business Quant data, Non-Current Assets over the past three periods registered $7.5 million, $7.8 million, and $8.0 million for Q2 2026, Q1 2026, and Q4 2025 respectively.